Introduction {#s1}
============

Glial cells (astrocytes and microglia) play a role in neuroinflammation and both cell types acquire a specific reactive phenotype when stimulated by lipopolysaccharide (LPS) ([@B1]). Activation of glial cells may lead to neuronal cell death. Activation of nicotinic α7 receptors (α7nAChR) suppresses the LPS-induced reactive phenotype of microglia and astrocytes and thus counteracts the deleterious effect regarding neuronal viability ([@B2]--[@B8]).

In the periphery the efferent fibers of the Vagus nerve activate α7nAChR on effector cells and inhibit inflammation ([@B9]). In the brain, fibers arising from the Nucleus tractus solitarii spread into both hemispheres and their activation may lead to a widespread central anti-inflammatory effect ([@B5], [@B10], [@B11]). It is currently insufficiently tested if this is also true for the fetal brain.

In a previous experiment we investigated the effect of α7nAChR stimulation on LPS-induced microglia-activation in a double hit model of sheep fetal microglia. In the current experiment, we extended this investigation to study the role of α7nAChR in fetal sheep astrocytes. These experiments may help to shed light on neurodevelopmental disorders such as autism spectrum disorder (ASD) or schizophrenia, that are thought to involve neuroinflammation during the fetal period ([@B12], [@B13]).

We hypothesized that ([@B1]) under exposure to LPS, α7nAChR agonist stimulation in fetal astrocytes augments their neuroprotective profile, while the inhibition reduces it; ([@B2]) a LPS double-hit (first *in vivo*, then *in vitro*) on astrocytes exacerbates these effects similar to microglia as demonstrated before. Using an *in vivo*---*in vitro* fetal sheep model ([@B14]), we validate these hypotheses via RNASeq analysis in primary fetal astrocyte cultures exposed to LPS in the presence of a selective α7nAChR agonist or antagonist. We compare these findings to the previously published results in identically conducted microglia experiments ([@B3], [@B15]).

Methods {#s2}
=======

Study Approval
--------------

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The respective *in vivo* and *in vitro* protocols were approved by the Committee on the Ethics of Animal Experiments of the Université de Montréal (Permit Number: 10-Rech-1560).

Anesthesia and Surgical Procedure
---------------------------------

The detailed protocol has been presented elsewhere ([@B3]). Briefly, we instrumented pregnant time-dated ewes at 126 days of gestation (dGA, \~0.86 gestation) with arterial, venous and amniotic catheters and ECG electrodes. Ovine singleton fetuses of mixed breed were surgically instrumented with sterile technique under general anesthesia (both ewe and fetus). In case of twin pregnancy the larger fetus was chosen based on palpating and estimating the intertemporal diameter. The total duration of the procedure was approximately 2 h. Antibiotics were administered to the mother intravenously (trimethoprim sulfadoxine 5 mg/kg body weight) as well as to the fetus intravenously and into the amniotic cavity (ampicillin 250 mg). Amniotic fluid lost during surgery was replaced with warm saline. The catheters exteriorized through the maternal flank were secured to the back of the ewe in a plastic pouch. For the duration of the experiment the ewe was returned to a metabolic cage, where she could stand, lie and eat *ad libitum* while we monitored the non-anesthetized fetus without sedating the mother. During postoperative recovery antibiotic administration was continued for 3 days. Arterial blood was sampled for evaluation of maternal and fetal condition and catheters were flushed with heparinized saline to maintain patency.

*In vivo* Experimental Protocol
-------------------------------

Postoperatively, all animals were allowed 3 days to recover before starting the experiments. On these 3 days, at 9.00 am 3 mL arterial plasma sample were taken for blood gasses and cytokine analysis. Each experiment commenced at 9.00 am with a 1 h baseline measurement followed by the respective intervention as outlined below. FHR and arterial blood pressure were monitored continuously (CED, Cambridge, UK, and NeuroLog, Digitimer, Hertfordshire, UK). Blood samples (3 mL) were taken for arterial blood gases, lactate, glucose, and base excess (ABL800Flex, Radiometer) and cytokines at the time points 0 (baseline), +1 (i.e., after LPS administration), +3, +6, +24, +48, and +54 h (i.e., before sacrifice at day 3). For the cytokine analysis, plasma was spun at 4°C (4 min, 4,000 g, Eppendorf 5804R, Mississauga, ON), decanted and stored at −80°C for subsequent ELISAs. After the +54 h (Day 3) sampling, the animals were sacrificed with an overdose of barbiturate (30 mg pentobarbital sodium, Fatal-Plus; Vortech Pharmaceuticals, Dearborn, MI) and a post mortem was carried out during which fetal gender and weight were determined. The fetal brain was then perfusion-fixed with 250 mL of cold saline followed by 250 mL of 4% paraformaldehyde and processed for histochemical analysis or dissected for cell culture (details see *in vitro* astrocytes culture paragraph). Fetal growth was assessed by body, brain, liver, and maternal weights.

Astrocytes Isolation and Purification
-------------------------------------

Briefly, fetal sheep brain tissues were obtained during sheep necropsy after completion of the *in vivo* experiment to conduct the *in vitro* study ([Figure 1](#F1){ref-type="fig"}). In the *in vivo* experiments, three *in utero* instrumented fetal sheep were treated intravenously with LPS (400 ng/fetus/day) derived from *E. coli* (Sigma Cat. no L5293, *E. coli* O111:B4, ready-made stock solution at a concentration of 1 mg/ml) on experimental days 1 and 2 at 10:00 am to mimic high levels of endotoxin in fetal circulation (so-called first LPS exposure or first hit). Three *in utero* instrumented fetal sheep were used as control receiving sterile saline. The instrumented fetuses were referred to as primary fetuses. In case of twins, twin fetuses were not instrumented, and their brains directly used for subsequent cell culture. Fetuses not exposed to LPS, either primary or twins, were designated "naïve" (no LPS exposure *in vivo*). Instrumented animals that received LPS *in vivo* were used for second hit LPS exposure *in vitro*.

![Experimental design of modulating glial α7nAChR signaling in a double-hit fetal sheep model. *In vivo, in vitro*, and RNAseq experiments are illustrated. *In vivo* study includes Control (saline) or LPS-exposed sheep fetuses. LPS was administered intravenously to the instrumented fetus at 400 ng/fetus/day for two consecutive days 24 h apart, so-called first hit, inducing fetal inflammatory response with rising IL-6, but without cardiovascular component. For the *in vitro* study, cultured cells (microglia or astrocytes) were derived from an *in vivo* Control animal, named Naïve, or from an *in vivo* LPS-exposed animal, named second hit (SH). There were 8 experimental groups: naïve Control (NC, vehicle *in vivo*, vehicle *in vitro*), naïve LPS (NL, sham in reference to α7nAChR manipulation), naïve exposed to α-Bungarotoxin (NB, i.e., α7nAChR inhibition, preincubated followed by LPS exposure), naïve exposed to AR-R17779 (NA, i.e., α7nAChR stimulation, preincubated followed by LPS exposure), and each respective second-hit groups (SH, LPS *in vivo*). Reproduced with permission ([@B16]).](fimmu-10-01063-g0001){#F1}

Astrocytes are the major adherent cell population in flask. Astrocytes were purified by passage into a new T75 flask for 4--5 times before any manipulations and treatments. After floating microglia collection, the adherent cells were detached by trypsinization (Trypsine 0.25% + EDTA 0.1%, Wisent Cat. No 325-043-EL) and re-plated into a new flask. Cells were cultured for another 7 days with 10% ready-to-use medium \[DMEM plus 1% penicillin/streptomycin, 1% glutamine, in addition with 10% heat-inactivated fetal bovine serum (Gibco, Canada Origin)\]. The cell passage procedure took 4--5 weeks until purified astrocytes could be used for the *in vitro* experiment. The cell culture conditions were 37°C, 5% CO~2~.

Pure astrocytes were plated into a 24-well plate at 1 × 10^5^ cells/mL with 10% DMEM for another 7 days, and then treated with LPS or saline for 6 h.

Cell-conditioned media were collected for cytokine analysis. To verify astrocytes purity, a portion of cells was plated into Lab-Tek 8 well chamber glass slide (Thermo Scientific) for immunocytochemistry (ICC) analysis. Glial fibrillary acidic protein (GFAP) was used as an astrocyte marker; cells were counterstained with Hoechst ([@B15]).

Astrocyte Cell Culture and Treatment
------------------------------------

Prior to exposure to LPS (Sigma Cat. no L5024, *E. coli* O127:B8) at a concentration of 100 ng/ul, cells were pretreated for 1 h with either 10 nM AR-R17779 hydrochloride (Tocris Bioscience Cat\# 3964), a selective α7nAChR agonist, or 100 nM α-Bungarotoxin (Tocris Bioscience Cat\# 2133), a selective α7nAChR antagonist. Optimal dose of AR-R17779 (A) or α-Bungarotoxin (B) was chosen based on a dose-response experiment with LPS. We have tested 0, 10, 100, and 1,000 nM of α-Bungarotoxin and 0, 1, 10, and 100 nM of AR-R17779 in the absence or presence of 100 ng/ul LPS, and measured IL-1β concentrations in cultured media as the endpoint. The 100 nM α-Bungarotoxin and 10 nM AR-R17779 were chosen because the cells responded in a linear range as indicated by IL-1β production.

AR-R17779 was reconstituted in DMSO as stock solution, serial dilutions were made to prepare the working stock; to obtain 10 nM AR-R17779 in concentration per well, 5 ul working stock was added well by well containing 500 ul media; only DMSO was added in control well, therefore, the DMSO concentration per well was 1%. α-Bungarotoxin was reconstituted with culture media into a stock solution and underwent serial dilutions.

In a complete cell culture experiment, we had four experimental groups: Control (naïve control), LPS100 (naïve LPS), LPS100+B100 (naïve LPS+B) and LPS100+A10 (naïve LPS+A). Second hit cell cultures were designed with the same pattern and divided into four experimental groups: Control (SHC), LPS100, LPS100+B100 and LPS100+A10.

Measurement of the Cytokine IL-1β in Cell Culture Media
-------------------------------------------------------

The approach is described elsewhere ([@B14], [@B16]). Briefly, IL-1β concentrations in cell culture media was determined by using an ovine-specific sandwich ELISA. Ninety-six-well plates were pre-coated with the mouse anti sheep monoclonal antibodies (IL-1β, MCA1658, Bio Rad AbD Serotec) at a concentration of 4 μg/ml on an ELISA plate at 4°C overnight. After 3 times wash with washing buffer (0.05% Tween 20 in PBS, PBST), plates were blocked for 1h with 1% BSA in PBST for plasma samples or 10% FBS for cell culture media. Recombinant sheep proteins (IL-1β, Protein Express Cat. no 968-405) were used as ELISA standard. All standards and samples were run in duplicate (50μl per well). Rabbit anti-sheep polyclonal antibodies (IL-1β, AHP423, Bio Rad AbD Serotec) at a concentration of 4 μg/ml were applied in wells and incubated for 30 min at room temperature. Plates were washed with washing buffer for 5--7 times between each step. Detection was accomplished by assessing the conjugated enzyme activity (goat anti-rabbit IgG-HRP, dilution 1:5000, Jackson ImmunoResearch, Cat. No 111-035-144) via incubation with TMB substrate solution (BD OptEIA TMB substrate Reagent Set, BD Biosciences Cat. No 555214); color development reaction was stopped with 2N sulphuric acid. Plates were read on an ELISA plate reader at 450 nm, with 570 nm wavelength correction (EnVision 2104 Multilabel Reader, Perkin Elmer). The sensitivity of IL-1β ELISA was 41.3 pg/ml. The intra-assay and inter-assay coefficients of variance were \<5 and \<10%, respectively.

RNAseq Approach
---------------

Nine replicates of astrocyte culture were studied, with one control and three treatment groups (Ctrl, LPS100, LPS+A10, LPS+B100) per replicate. Four replicates were used for RNAseq based on the RNA quality, of which 3 replicates of naive, one replicate of second-hit, with one treatment missing in this second-hit replicate (agonist treatment), fifteen samples in total were assessed with RNAseq in this study ([Table 1](#T1){ref-type="table"}).

###### 

Sample inventory for RNAseq study in astrocytes samples.

  **Biological replicates**   **Serial\#**   **Sample**   **Treatment**   **LPS hit number**
  --------------------------- -------------- ------------ --------------- --------------------
  Naïve R1                    1              4414T1       Ctrl            0
                              2              4414T1       LPS100          1
                              3              4414T1       LPS100+B100     1
                              4              4414T1       LPS100+A10      1
  Naïve R2                    5              4414T2       Ctrl            0
                              6              4414T2       LPS100          1
                              7              4414T2       LPS100+B100     1
                              8              4414T2       LPS100+A10      1
  Naïve R3                    9              4502P        Ctrl            0
                              10             4502P        LPS100          1
                              11             4502P        LPS100+B100     1
                              12             4502P        LPS100+A10      1
  Second hit R1               13             711P         Ctrl            1
                              14             711P         LPS100          2
                              15             711P         LPS100+B100     2

*Four replicates were used for RNAseq, with one control and three treatment groups (Ctrl, LPS100, LPS100+A10, LPS100+B100) per replicate. There were 3 replicates of naïve, one replicate of second-hit, with one treatment missing in this second-hit replicate (second-hit + Agonist), fifteen samples in total were assessed with RNAseq in this study. The instrumented fetuses were designated as primary fetus, identified as animal ID+P (stands for primary), whereas animal ID+T stands for non-instrumented twins*.

### RNA Extraction and Quantification

We used Qiagen RNeasy Mini Kit (Cat no 74104) for RNA extraction. RNA quantity and quality (RNA integrity number, RIN) was established by using a RNA Nano Chip (Agilent RNA 6000 Nano Chips) with Agilent 2,100 BioAnalyzer. All samples had an acceptable RIN value ranging from 8.4 to 9.6. A total of 12 naïve astrocyte cultures from four sets of replicates was selected for RNA sequencing at high throughput, as well as three second hit astrocyte cultures ([Table 1](#T1){ref-type="table"}).

RNAseq libraries were prepared using the TruSeq stranded mRNA kit (Illumina cat \#20020594) and quality control was performed on the Agilent TapeStation and using the KAPA SYBRFAST qPCR kit (Kapa Biosystems, Roche). Single read 100-bp sequencing was performed in rapid mode on a HiSeq 2,500 (Illumina Inc.) at the University of Washington Northwest Clinical Genomics Lab (Department of Pathology).

RNAseq Data Analyses
--------------------

### Astrocytes

The goal for this analysis was to compare the single hit LPS treated samples to Control, as well as making comparisons between the LPS treated samples (e.g., testing for changes due to the additional agonist or antagonist pre-treatment). The second hit samples had no replicates, so we could only make the directed comparisons between the single and second hit samples. For example, comparing the single and second hit LPS treated samples, as before ([@B3]).

We aligned the reads to the Oar_v3.1 transcriptome using the salmon aligner ([@B17]), which infers the most likely transcript for each read using a quasi-mapping algorithm. We then "collapsed" the transcript read counts to the gene level by summing up the reads for each gene\'s transcripts, using the Bioconductor tximport package ([@B18]). In the end, we had a set of read counts per gene, for each sample.

Four replicates were used for RNAseq, with one control and three treatment groups Ctrl, LPS, LPS+A10, LPS+B100) per replicate. There were 3 replicates of naïve, one replicate of second-hit, with one treatment missing in this second-hit replicate (second-hit + agonist, SHA), fifteen samples in total were assessed with RNAseq in this study ([Table 1](#T1){ref-type="table"}). The instrumented fetuses were designated as primary fetus, identified as animal ID+P (stands for primary), whereas animal ID+T stands for non-instrumented twins.

To compare astrocytes transcriptomes, we used the Bioconductor edgeR package ([@B19]), to fit a generalized linear model with a negative binomial link function, and made comparisons between groups using quasi-likelihood F-tests.

We fitted the model described above, including the treatment effect for each animal, and made the comparisons, incorporating a fold change criterion into the test. In other words, the conventional test for a difference is between the null hypothesis H~0:~ β = 0 vs. the alternative hypothesis H~A:~ β ≠ 0, but this may include very small changes that are likely to be biologically meaningless. One alternative to exclude such genes is to use a *post hoc* fold change adjustment, where we select genes based on the observed fold change between groups. This is problematic because we ignore the imprecision in our estimate of fold change. A better method is to incorporate the fold change into our inference, where we test H~0~ : β ≤ \|c\| against the alternative H~A~ : β ≥ \|c\|, for some constant fold change. By doing this, we are testing to see if we have evidence that the underlying population differences are larger than a given fold change, rather than simply testing that our sample data fulfill those criteria. We used a 1.5-fold change, and a false discovery rate (FDR) of 0.05 as criteria to define significantly differentially expressed genes, meaning that we expect that there are, at most, 5% false positives in our set of significant genes.

### Microglia---Astrocytes Transcriptome Comparisons

We also made comparisons to the existing RNAseq data that our lab generated using primary cultures of fetal sheep microglia from the identical experimental design in three biological replicates. This data has been published and the data set is accessible online ([@B14]).

We downloaded the FASTQ data from SRA and processed using the same salmon/tximport pipeline we used for the astrocyte samples. The only difference was in the modeling step, where we converted the count data to log counts/million and estimated observation-level weights using the limma voom function. We also computed sample-specific weights that are intended to down-weight any samples that are not very similar to other samples of the same type. We then fit a conventional weighted linear model and made empirical Bayes adjusted contrasts between various groups. By incorporating sample-specific weights we were able to account for a single sample (LPS100 treated animal 4414T), which had significantly fewer reads, perhaps due to some technical problems.

### Venn Diagrams

We sought to learn which genes are unique to a given comparison, and which are shared between two or more of those comparisons. Thus, we generated Venn diagrams for three sets of comparisons. We made a Venn diagram for the three comparisons of treated vs. control, a two-way Venn diagram of the agonist + LPS vs. either LPS alone or LPS plus antagonist (this shows that there is very little difference between LPS and LPS plus antagonist), and finally we made a Venn diagram of the one-hit vs. two-hit for all three treatments. The genes in any intersection between comparisons had to be significantly differentially expressed in both (or all three, depending on the intersection) of the comparisons. In addition, the direction of change had to be the same as well. For example, if a given gene was differentially expressed in LPS100 vs. control and LPS100+A10 vs. control, and it is either up or down-regulated in both comparisons as well, then it was listed in the intersection between those two comparisons. If it was significant in both comparisons, but was up-regulated in one comparison, but down-regulated in the other, then it was listed in the unique portion of the Venn diagram for each comparison.

Statistical Analyses and Data Repository
----------------------------------------

Generalized estimating equations (GEE) modeling approach was used to assess the effects of LPS and drug treatments on IL-1β. We used a linear scale response model with LPS/drug treatment group (main term "treatment") and presence or absence of second hit exposure (main term "hit") as predicting factors to assess their interactions using maximum likelihood estimate and Type III analysis with Wald Chi-square statistic. SPSS Version 25 was used for these analyses (IBM SPSS Statistics, IBM Corporation, Armonk, NY). Significance was assumed for *p* \< 0.05. Results are provided as median {25--75} percentiles. Not all measurements were obtained for each animal studied, as indicated.

Ingenuity Pathway Analysis (IPA, Qiagen, 2019) was used for identification of signaling pathways unique to each treatment.

The raw RNAseq data has been deposited under GEO accession number *[GSE123713](GSE123713)*. The analytical pipeline to allow reproduction of this analysis, in the form of a Rmarkdown document, will be made available upon request. Statistics from all comparisons (t-statistics, log fold changes, FDR values, dynamically linked Venn diagrams) can be found in supplemental document under the doi: [10.5281/zenodo.2609202](https://doi.org/10.5281/zenodo.2609202).

Results and Discussion {#s3}
======================

Cytokine Secretion Profile
--------------------------

The fetal *in vivo* exposure to LPS resulted in a rise of IL-6 as reported ([@B14], [@B16]).

The absolute values of IL-1β produced by naive (first hit) and second hit astrocytes at baseline, under LPS exposure and with preceding agonist or antagonist incubation are presented in [Table 2](#T2){ref-type="table"}. As reported, LPS treatment induced IL-1β increase in astrocytes ([@B14]). There was no difference in first and second hit astrocytes at baseline or when exposed to LPS alone. Our focus here was on the effect of α7nAChR modulation on LPS-triggered IL-1β production. Consequently, we expressed the data as fold-changes compared to sham treatment (LPS, [Figure 2](#F2){ref-type="fig"}, LEFT). We present the response of primary microglia cultures side-by-side ([Figure 2](#F2){ref-type="fig"}, RIGHT) in form of re-analysis of previously published data ([@B3]).

###### 

Astrocytes IL-1β secretion expressed as absolute values[^\*^](#TN1){ref-type="table-fn"} in pg/ml (median and 25--75%).

  **LPS exposure**   **Ctrl**   **LPS**          **B100**        **A10**
  ------------------ ---------- ---------------- --------------- ----------------
  Single hit         1 (1,25)   429 (358,1034)   336 (285,928)   750 (439,1495)
  Second hit         1 (1,1)    16 (15,16)       20 (17,22)      99 (95, 103)

*Values set to 1 where no signal was detected by the cytokine assay to compute fold-changes for [Figure 2](#F2){ref-type="fig"}*.

![**(Left)** IL-1β secretion in ovine primary astrocyte cultures in response to 6 h LPS exposure without or with pre-incubation with α7nAChR antagonist (B100) or agonist (A10) for 1 h. Single hit, *in vitro* only LPS exposure; second hit, *in vivo* systemic and subsequent *in vitro* LPS exposure 4 to 5 weeks later. Y axis shows fold changes in IL-1β in relation to the levels of sham treatment (LPS). Generalized estimating equations (GEE) modeling results are presented in text and no significance marks are provided in the figure. For both box plots, an asterisk represents an extreme outlier (a value more than 3 times the interquartile range from a quartile). A circle marks outlier with values between 1.5 and 3 box lengths from the upper or lower edge of the box. Briefly, we found significant main term effects (*p* = 0.019) "treatment" (LPS and α7nAChR drug) as well as main term "hit" (*p* = 0.010), i.e., the contribution of *in vivo* LPS exposure, the second hit effect on the IL-1β secretion profile. Results are provided as median {25--75} percentiles. **(Right)** Identical experimental results from microglia studies are presented for comparison. The main terms "hit" and "treatment" were not significant (*p* = 0.716 and *p* = 0.666, respectively), but their interaction was significant (*p* = 0.026, cf. Figure 1 in ([@B3]) where the original results have been published.](fimmu-10-01063-g0002){#F2}

For astrocytes, the main terms "hit" and "treatment" as well as their interaction were significant (all p\<0.001). Agonistic stimulation of the α7nAChR appeared, surprisingly, to result in a relative increase of IL-1β concentration, further potentiated in second hit astrocytes. This effect was absent in first hit astrocytes cultures treated with the α7nAChR antagonist and less pronounced but present in the second hit cultures.

For microglia, the main terms "hit" and "treatment" were not significant (*p* = 0.716 and *p* = 0.666, respectively), but their interaction was significant \[*p* = 0.026, cf. Figure 1 in ([@B3])\].

The overall pattern of IL-1β levels in response to LPS exposure with prior α7nAChR stimulation was inverted in astrocytes compared to microglia. In astrocytes, both first hit and second hit cell cultures responded under inhibition of α7nAChR with relative decrease of IL-1β production. In microglia, in contrast, first hit (naive) cultures behaved intuitively under the same conditions, showing a rise in IL-1β production. However, second hit microglia cultures, similar to second hit astrocytes, showed a drop in IL-1β production with α7nAChR inhibition. In contrast again, agonistic α7nAChR stimulation in both second hit glia cultures resulted in higher than first hit IL-1β production, albeit, the magnitude of this rise was \~3.5-fold larger in astrocytes suggesting differences in sensitization of these glia cells to previous LPS exposure *in utero*. These counter-intuitive findings of α7nAChR stimulation in astrocytes on the individual IL-1β secretion stand in contrast to the transcriptome-level findings we discuss below. We attempt to tie together these results in the general discussion section.

Whole Transcriptome Analysis
----------------------------

Mapped reads aligned to any transcript from the Oar_v3.1 transcriptome at 66% which is good. Principal component analysis (PCA) showed large differences between the different treatment groups, and much smaller differences within each group, indicating that we have a good signal with likely many differentially expressed genes (DEG) to be found ([Figure 3](#F3){ref-type="fig"}).

![Static 3D plot of the astrocyte RNAseq data with single and double-hit LPS treatment. The angle of the plot was chosen to give the best viewpoint to show differences between the sample types. Note that controls and α7nAChR agonistically pre-treated astrocytes cluster together and separately from those exposed to LPS w/o or with antagonistic α7nAChR pre-treatment. Note here that there are three of the LPS_100_1\_hit samples in the plot shown in this figure; it just so happens that the third sample is obscured by the uppermost LPS+B100_1\_hit sample.](fimmu-10-01063-g0003){#F3}

We present in [Table 3](#T3){ref-type="table"} the number of genes for each comparison as well as the top ten signaling pathways IPA identified. The results of the analysis on the entire data set are also accessible with search function via this repository.

###### 

Ingenuity Pathway Analysis of differentially expressed genes from the fetal sheep astrocytes whole transcriptome analysis: naïve and second hit astrocytes after modulation of α7nAChR signaling.

  **comparison**                           **\# genes**   **Top 10 signaling pathways**                                                        **-log(*p*-value)**
  ---------------------------------------- -------------- ------------------------------------------------------------------------------------ ---------------------
  Single hit: LPS100 vs. Control           1835           NF-κB Signaling                                                                      15.8
                                                          Role of Pattern Recognition Receptors in Recognition of Bacteria & Viruses           14
                                                          **Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis**   13.7
                                                          **Dendritic Cell Maturation**                                                        13
                                                          **Neuroinflammation Signaling Pathway**                                              12.8
                                                          **Role of IL-17A in Arthritis**                                                      12.2
                                                          Activation of IRF by Cytosolic Pattern Recognition Receptors                         11.6
                                                          Death Receptor Signaling                                                             11.3
                                                          Th1 and Th2 Activation Pathway                                                       10.7
                                                          TREM1 Signaling                                                                      10.5
  Single hit: LPS100+A10 vs. Control       1725           **NF-κB Signaling**                                                                  14.7
                                                          **Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis**   13.7
                                                          Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis            13.1
                                                          Granulocyte Adhesion and Diapedesis                                                  12.7
                                                          Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses         12.5
                                                          Hepatic Cholestasis                                                                  12.5
                                                          Toll-like Receptor Signaling                                                         11.7
                                                          Axonal Guidance Signaling                                                            11.5
                                                          IL-10 Signaling                                                                      11.1
                                                          Neuroinflammation Signaling Pathway                                                  10.7
  Single hit: LPS100+B100 vs. Control      1744           NF-κB Signaling                                                                      16.8
                                                          **Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis**   16
                                                          Dendritic Cell Maturation                                                            15.9
                                                          Neuroinflammation Signaling Pathway                                                  15
                                                          Role of Pattern Recognition Receptors in Recognition of Bacteria & Viruses           14.8
                                                          TREM1 Signaling                                                                      12.8
                                                          Role of IL-17A in Arthritis                                                          12.7
                                                          T Cell Exhaustion Signaling Pathway                                                  11.9
                                                          **Toll-like Receptor Signaling**                                                     11.8
                                                          **PI3K Signaling in B Lymphocytes**                                                  11.6
  Single hit: LPS100+A10 vs. LPS100        273            Granulocyte Adhesion and Diapedesis                                                  6.23
                                                          Pathogenesis of Multiple Sclerosis                                                   5.81
                                                          Agranulocyte Adhesion and Diapedesis                                                 5.12
                                                          Th1 and Th2 Activation Pathway                                                       4.45
                                                          Th2 Pathway                                                                          4.4
                                                          LPS/IL-1 Mediated Inhibition of RXR Function                                         3.81
                                                          NF-κB Signaling                                                                      3.71
                                                          Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis            3.63
                                                          Inhibition of Angiogenesis by TSP1                                                   3.33
                                                          STAT3 Pathway                                                                        3.25
  Single hit: LPS100+B100 vs. LPS100       0                                                                                                   
  Single hit:                              292            Granulocyte Adhesion and Diapedesis                                                  5.25
  LPS100+A10 vs. LPS100+B100                              Agranulocyte Adhesion and Diapedesis                                                 4.99
                                                          LPS/IL-1 Mediated Inhibition of RXR Function                                         4.38
                                                          Hepatic Fibrosis / Hepatic Stellate Cell Activation                                  4.35
                                                          NF-κB Signaling                                                                      4.33
                                                          Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis            4.18
                                                          Pathogenesis of Multiple Sclerosis                                                   3.97
                                                          STAT3 Pathway                                                                        3.94
                                                          p53 Signaling                                                                        3.57
                                                          Sirtuin Signaling Pathway                                                            3.36
  LPS100: single hit vs. second hit        3761           Hepatic Fibrosis / Hepatic Stellate Cell Activation                                  10.7
                                                          Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes                      7.69
                                                          Leukocyte Extravasation Signaling                                                    6.82
                                                          Signaling by Rho Family GTPases                                                      6.16
                                                          Iron homeostasis signaling pathway                                                   6.02
                                                          LXR/RXR Activation                                                                   5.36
                                                          Epithelial Adherens Junction Signaling                                               4.99
                                                          Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis            4.96
                                                          Axonal Guidance Signaling                                                            4.91
                                                          Tec Kinase Signaling                                                                 4.82
  LPS100+A10: single hit vs. second hit    3307           Hepatic Fibrosis / Hepatic Stellate Cell Activation                                  13
                                                          Leukocyte Extravasation Signaling                                                    8.79
                                                          Neuroinflammation Signaling Pathway                                                  7.18
                                                          Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes                      6.99
                                                          Axonal Guidance Signaling                                                            6.93
                                                          Phagosome Formation                                                                  6.85
                                                          Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses         6.67
                                                          Agranulocyte Adhesion and Diapedesis                                                 6.24
                                                          GP6 Signaling Pathway                                                                6.1
                                                          Granulocyte Adhesion and Diapedesis                                                  5.92
  LPS100+B100: single hit vs. second hit   3860           Hepatic Fibrosis / Hepatic Stellate Cell Activation                                  8.89
                                                          Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes                      8.03
                                                          Leukocyte Extravasation Signaling                                                    7.26
                                                          Epithelial Adherens Junction Signaling                                               5.94
                                                          Iron homeostasis signaling pathway                                                   5.78
                                                          Signaling by Rho Family GTPases                                                      5.51
                                                          Axonal Guidance Signaling                                                            5.18
                                                          Endothelin-1 Signaling                                                               5.04
                                                          Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis       5.01
                                                          Phagosome Formation                                                                  4.99

*Differential analysis of count data was done with the Bioconductor limma package. Differentially expressed genes were selected, based on a 1.5-fold change and an FDR \< 0.05. Up regulation and down regulation represent positive and negative log2 fold changes, respectively. For details on "raw gene" level, see our [GitHub](https://github.com/martinfrasch/astrocytes_RNAseq) repository or directly here. Bold font highlights pathways common with microglia*.

Orange: positive z-score; blue: negative z-score. For further details as raw data and visualized activity patterns see [GitHub](https://github.com/martinfrasch/astrocytes_RNAseq/tree/master/reports/IPA_TIFFs_and_xls).

*Significant genes in astrocytes cultures at an FDR \< 0.05 and a 1.5-fold change sorted on log(p-value)*.

PCA showed two transcriptome clusters ([Figure 3](#F3){ref-type="fig"}):

1\) Control, LPS single-hit and second-hit astrocytes pre-treated with α7nAChR agonist and

2\) LPS single-hit and second-hit astrocytes pre-treated with α7nAChR antagonist.

That is, a pro-inflammatory transcriptome astrocyte phenotype acquired *in vivo* or *in vitro* by LPS stimulation is reversed with α7nAChR agonistic stimulation. Conversely, α7nAChR inhibition potentiates the pro-inflammatory astrocytic phenotype. The PCA level observations are substantiated further by the IPA analysis of key signaling pathways presented in [Table 3](#T3){ref-type="table"}. The visualization of the up or down regulation of the implicated pathways can be accessed on [GitHub](https://github.com/martinfrasch/astrocytes_RNAseq/tree/master/reports/IPA_TIFFs_and_xls) in its entirety. Here we focus on some key findings in top 10 signaling pathways. LPS treatment triggered activation of pro-inflammatory signaling pathways NF-κB and neuroinflammation. Compared to LPS exposure alone, pretreatment with α7nAChR agonist reversed both signaling pathways activation. Conversely, pretreatment with α7nAChR antagonist up regulated these pro-inflammatory pathways. Albeit the pattern overall was similar to the effect of LPS alone, activation of these signaling pathways under α7nAChR blockade stood out: Toll-like receptor signaling and PI3K signaling. Direct comparison of α7nAChR agonistic stimulation or inhibition yielded reduced activity of NF-κB and STAT3 pathways due to activation of α7nAChR, consistent with the expected intracellular anti-inflammatory effect of α7nAChR agonism. Another notable pathway activated in α7nAChR agonistically treated astrocytes was the Sirtuin signaling. Activation of this pathway in neurons and astrocytes has been implicated in AMPK-dependent neuroprotection from ischemic stroke ([@B20], [@B21]). Adenosine monophosphate kinase (AMPK) is a rapid key regulator of neuronal energy homeostasis implicated in fetal neuroinflammation ([@B22]).

The second half of [Table 3](#T3){ref-type="table"} documents some effects of astrocytes memory of LPS exposure *in vivo* when re-exposed *in vitro* (second hit effect). For comparison to microglial activity, see [Table 4](#T4){ref-type="table"}. Notably, we found a perturbation of the iron homeostasis signaling pathway in second hit LPS treated astrocytes which persisted under pre-treatment with α7nAChR antagonist but was reversed with α7nAChR agonist. Similar to our finding of second hit signature in microglia, here we observed hemoxygenase (HMOX)1 gene down regulation in second hit astrocytes compared to first hit cultures ([@B3], [@B15]). HMOX1 is a key gene of iron homeostasis. We observed a similar phenomenon in second hit fetal microglia compared to single hit microglia ([@B15]).

###### 

Ingenuity Pathway Analysis of differentially expressed genes from the fetal sheep microglia whole transcriptomes analysis.

  **Comparison**               **\# genes**   **Top 10 signaling pathways**                                                        **-log(p-value)**
  ---------------------------- -------------- ------------------------------------------------------------------------------------ -------------------
  LPS100 vs. Control           1779           **Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis**   16.7
                                              **Dendritic Cell Maturation**                                                        12.9
                                              iNOS Signaling                                                                       12.6
                                              **Role of IL-17A in Arthritis**                                                      12.5
                                              IL-10 Signaling                                                                      11.8
                                              Role of Tissue Factor in Cancer                                                      11.6
                                              Production of Nitric Oxide and Reactive Oxygen Species in Macrophages                11.1
                                              **Neuroinflammation Signaling Pathway**                                              10.9
                                              Toll-like Receptor Signaling                                                         10.7
                                              CD40 Signaling                                                                       10
  LPS100+A10 vs. Control       4721           Molecular Mechanisms of Cancer                                                       14.1
                                              Colorectal Cancer Metastasis Signaling                                               11.2
                                              Toll-like Receptor Signaling                                                         11
                                              **NF-κB Signaling**                                                                  10.6
                                              **Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis**   10.4
                                              PI3K Signaling in B Lymphocytes                                                      10.4
                                              Role of Tissue Factor in Cancer                                                      10.3
                                              B Cell Receptor Signaling                                                            9.83
                                              TREM1 Signaling                                                                      7.83
                                              Protein Kinase A Signaling                                                           7.81
  LPS100+B100 vs. Control      4049           **Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis**   13.6
                                              **PI3K Signaling in B Lymphocytes**                                                  11.4
                                              Production of Nitric Oxide and Reactive Oxygen Species in Macrophages                10.2
                                              Molecular Mechanisms of Cancer                                                       10.2
                                              Activation of IRF by Cytosolic Pattern Recognition Receptors                         10.2
                                              IL-10 Signaling                                                                      9.63
                                              B Cell Receptor Signaling                                                            9.55
                                              iNOS Signaling                                                                       9.21
                                              Role of Tissue Factor in Cancer                                                      9.06
                                              **Toll-like Receptor Signaling**                                                     8.93
  LPS100+A10 vs. LPS100        8                                                                                                   
  LPS100+B100 vs. LPS100       0                                                                                                   
  LPS100+A10 vs. LPS100+B100   1132           T Cell Exhaustion Signaling Pathway                                                  5.46
                                              Dendritic Cell Maturation                                                            5.43
                                              Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis       5.42
                                              Altered T Cell and B Cell Signaling in Rheumatoid Arthritis                          5.22
                                              Th17 Activation Pathway                                                              5.16
                                              Leukocyte Extravasation Signaling                                                    4.81
                                              Superpathway of Cholesterol Biosynthesis                                             4.8
                                              IL-10 Signaling                                                                      4.49
                                              Role of Tissue Factor in Cancer                                                      4.31
                                              Th1 and Th2 Activation Pathway                                                       4.26

*Differential analysis of count data was done with the Bioconductor limma package. Differentially expressed genes were selected, based on a 1.5-fold change and an FDR \< 0.05. Up regulation and down regulation represent positive and negative log2 fold changes, respectively. For details on "raw gene" level, see our [GitHub](https://github.com/martinfrasch/astrocytes_RNAseq) repository or directly here. Bold font highlights signaling pathways common with astrocytes. Orange: positive z-score; blue: negative z-score. For further details as raw data and visualized activity patterns see [GitHub](https://github.com/martinfrasch/astrocytes_RNAseq/tree/master/reports_micro/micro_IPA_TIFFs_and_xls)*.

*Significant genes in microglia cultures at an FDR \< 0.05 and a 1.5-fold change sorted on log(p-value)*.

Together, observations on Sirtuin and iron homeostasis signaling reinforce the previously reported dual role of energy metabolism in determining inflammatory phenotype in glia cells ([@B3], [@B15]).

Based on the IPA analysis within the *Ve*nn diagrams, the top down-regulated signaling pathway unique to LPS treatment was Ephrin A signaling \[log(*p*-value) 3.21, [Table 5](#T5){ref-type="table"}\]. Analysis of genes unique to α7nAChR agonist treatment showed a reduction of this down-regulation \[log(*p*-value)1.58, [Table 5](#T5){ref-type="table"}\]. Analysis of genes unique to α7nAChR antagonist treatment had no significant effect on this signaling pathway ([Table 5](#T5){ref-type="table"}). Ephrin signaling has been implicated in neuroprotective astrocyte phenotype ([@B23]). Our findings suggest a neuroprotective effect of α7nAChR agonism on ephrin signaling pathway.

###### 

Genes unique to LPS, agonistic stimulation or inhibition of α7nAChR in single hit astrocytes cultures.

                               **Top 10 signaling pathways**                  **-log(*p*-value)**
  ---------------------------- ---------------------------------------------- ---------------------
  **Genes unique to LPS100**   Ephrin A Signaling                             3.21
                               P2Y Purigenic Receptor Signaling Pathway       2.72
                               Role of p14/p19ARF in Tumor Suppression        2.55
                               Thiamin Salvage III                            2.2
                               Melanoma Signaling                             2.14
                               Lymphotoxin β Receptor Signaling               2.03
                               CCR3 Signaling in Eosinophils                  1.96
                               CD40 Signaling                                 1.84
  **Genes unique to A10**      Germ Cell-Sertoli Cell Junction Signaling      9.13
                               Integrin Signaling                             7.4
                               Actin Cytoskeleton Signaling                   5.84
                               Leukocyte Extravasation Signaling              5.81
                               Sertoli Cell-Sertoli Cell Junction Signaling   5.58
                               GDP-glucose Biosynthesis                       5.49
                               Glucose and Glucose-1-phosphate Degradation    5.24
                               Phagosome Formation                            4.84
                               Signaling by Rho Family GTPases                4.71
                               HGF Signaling                                  4.6
  **Genes unique to B100**     Apelin Cardiomyocyte Signaling Pathway         5.54
                               Adrenomedullin signaling pathway               4.09
                               Dendritic Cell Maturation                      3.23
                               Endothelin-1 Signaling                         3.2
                               UVA-Induced MAPK Signaling                     3.2
                               Renin-Angiotensin Signaling                    2.97
                               Role of NFAT in Cardiac Hypertrophy            2.95
                               Phagosome Formation                            2.95
                               GP6 Signaling Pathway                          2.91
                               Wnt/Ca+ pathway                                2.89

Consistent with the notion of cholinergic signaling involved in stress axis regulation ([@B3]), POMC was the second (by IPA ranking) highest up-regulated gene under cholinergic agonist treatment, with a log ratio of 3.388 (Cf. [GitHub repository](https://github.com/martinfrasch/astrocytes_RNAseq/blob/master/venns/unique_xls/astrocytes%20genes%20-%20IPA%20molecules%20-%20unique%20to%20LPS100%2BA10%20vs%20Ctrl%201hit%20FINAL%202019-03-26.xls)).

Comparison to Fetal Sheep Microglial Transcriptome
--------------------------------------------------

PCA in [Figure 4](#F4){ref-type="fig"} (top) shows that the main differences between astrocytes and microglia RNAseq data are captured on the first two principal components, so a 2D plot may be more useful ([Figure 4](#F4){ref-type="fig"}, bottom). The intra-group variability is smaller for the astrocytes compared to the microglia. This may have to do with the total library sizes: there were several microglia samples with very few reads that aligned to any known transcript.

![**(Top)** PCA plot of microglia and astrocyte samples. Here we can see that astrocytes and microglia separate on the first principal component, and the second principal component captures the LPS treatment differences. The third principal component captures some intra-treatment variability for the microglia samples, particularly for one of the LPS treated microglia samples. **(Bottom)** PCA plot of microglia and astrocyte samples, showing just the first two principal components. The largest differences appear to be between the cell types.](fimmu-10-01063-g0004){#F4}

We compared the IPA-identified top signaling pathways in microglia and astrocytes under the LPS and α7nAChR signaling manipulation. [Table 4](#T4){ref-type="table"} presents the number of genes for each comparison and the corresponding findings of the IPA signaling pathway analysis. Overall, the response patterns to LPS and modulation of α7nAChR signaling were similar between the two glia cell types. The signaling pathways common to both astrocytes and microglia are bolded in [Tables 3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}. Intuitively, common pathways activated due to LPS included neuroinflammation signaling and NF-κB signaling in some, but not all comparisons. However, overall, the overlap on the level of signaling pathway was rather minimal which may explain the strong separation by cell type on PCA. It is remarkable that astrocytes, not microglia---the primary immune cells of the brain, were characterized by unique inhibition patterns of STAT3 pathway due to agonistic stimulation of α7nAChR prior to LPS exposure.

The presented astrocytes---microglia comparison has limitations. The differences between the two cell types may be exaggerated by the inevitable technical differences (e.g., reagents). However, all these experiments were run from the same cohort, same animals (in some cases), at adjacent times and by the same people.

Do Fetal Neuroinflammation and Stress Mediate an Increased Risk for Autism Spectrum Disorder?
---------------------------------------------------------------------------------------------

LPS effects on key genes involved in stress axis activity raised the question about the poorly understood role of astrocytes in the signaling pathways of neuroinflammation and prenatal stress (PS) ([@B24]).

Indeed, PS is accompanied by inflammation in the mother and offspring ([@B24]--[@B29]). Both, PS and fetal neuroinflammation have been implicated in the etiology of ASD ([@B30], [@B31]). PS increases expression of glutamate (Glu) transporter vGluT1 (SLC17A7) resulting in higher levels of GLT1 ([@B32], [@B33]).

Here, we sought to verify if the exposure of fetal astrocytes to LPS induces upregulation of Glu transporters in glia akin to PS ([@B32], [@B33]).

Given the known relationship between PS and VGLUT1 expression, we used IPA to annotate VGLUT1 gene network with our findings to test for evidence that the network is being perturbed by LPS treatment. Across all treatment comparisons, two DEGs were identified in astrocytes (common to all comparisons): JAK2 (2.732 (log ratio) upregulated, FDR 3.91E-05) and SLC1A2 (2.350 upregulated, FDR 1.80E-04). JAK1 signaling is involved in glucocorticoid receptor signaling ([@B34]) and JAK1/2 signaling is involved in iron homeostasis signaling pathways([@B35]), whereas JAK/Stat is involved in IL-6 signaling pathways. SLC1A2 is also known as GLT-1 or glial high affinity glutamate transporter; it is implicated in glutamate receptor signaling and neuroinflammation signaling pathways ([@B36]). Upregulation of glial GLT-1 in the hippocampus has been reported after chronic stress due to its control by glucocorticoids ([@B37]--[@B39]).

Again assessing the present findings together with the previously published RNAseq data from the identical experiment in ovine fetal microglia ([@B3]), we found GLT-1 to be upregulated in microglia and astrocytes regardless cholinergic manipulation (for details see [GitHub repository](https://github.com/martinfrasch/astrocytes_RNAseq/blob/master/description.html)). Albeit both pure primary cultures were exposed to LPS, we found the up regulation of JAK2 to be unique to astrocytes. This finding is conceptually in line with studies reporting brain cell-specific signaling pathways behavior in response to IL-1β ([@B40]). Much remains to be learned about the differences between second messenger signaling cascades involved in astrocytes, microglia and neurons in the developing fetal brain exposed to inflammatory stimuli. Furthermore, there is still a paucity of data about differences across the species for these signaling pathways.

General Discussion
------------------

Fetal sheep is the classic model of fetal physiology and neuroscience ([@B41]). It has been used successfully for both integrative physiological as well as genomic studies. In the present study, we expand the recently published series of experiments in the same animal model using primary microglia cultures to now include primary astrocytes cultures ([@B3], [@B14]--[@B16]).

Acetylcholine is synthesized by cultured microglia and astrocyte in mouse and rat ([@B42], [@B43]), however, there is no information from other species. It is plausible that the fetal sheep brain astrocytes in culture produce acetylcholine, because they appear to respond to α7nAChR stimulation. However, we do not know how much acetylcholine is produced, and whether or not the speculated endogenous acetylcholine can activate the α7nAChR. This remains worthwhile to investigate in future studies.

The antagonist drug for α7nAChR we used, α-bungarotoxin, is a selective inhibitor for α7 receptors acting by preventing the opening of nicotinic receptor-associated ion channels (Tocris α-bungarotoxin datasheet). By using optimized dose, we treated our astrocyte cells with α-bungarotoxin 1 h prior to LPS exposure, which would block LPS-induced cytokine production in the cells.

LPS exposure had the anticipated effect of increasing IL-1β production in astrocytes and we observed this consistently on the transcriptome level. However, our findings on protein level following pre-incubation with α7nAChR antagonist or agonist do not align with those on the transcriptome level: present results on protein level do not show a clear hypothesized effect of α7nAChR agonism or antagonism on LPS secretion in ovine fetal astrocytes. Such discordant behavior on protein and transcriptome levels has been reported and studied systematically to represent the rule rather than an exception to cellular biology in general ([@B44]).

Future studies will need to explore the protein responses in more depth and in different species to further delineate astrocytic behavior under α7nAChR stimulation, especially the peculiarly opposite effect of endotoxin memory in astrocytes and microglia on IL-1β secretion.

Microglia---astrocyte ensemble interactions need to be studied to bridge the methodological gap between *in vitro* experimental design and the *in situ* physiology. This can be done in co-cultures, feasible in ovine species, for example ([@B14]). Recent study in mice highlighted the importance of microglia---astrocyte interactions for understanding the polarization dynamics of astrocytes ([@B45]).

In an adult rodent model, cholinergic signaling reduced stress responsiveness via cortisol releasing hormone (CRH) receptor 1 with positive behavioral changes ([@B46]). We identified POMC as up regulated under α7nAChR stimulation. Considering that CRH is an upstream regulator of POMC, another question for future studies is whether we can implicate a direct interaction with the CRH receptor 1 in the developing brain.

We found that within its interaction network, GLT-1 was upregulated in microglia and astrocytes regardless of cholinergic manipulation, while the up-regulation of JAK1/2 was unique to astrocytes. This is in line with studies showing brain region specific overexpression of vGluT-1 (SLC17A7) both due to endotoxin stress and due to PS and puts the LPS exposure in the context of a more general brain stress exposure paradigm presenting with shared response patterns of neuroinflammation and metabolic adaptations in astrocytes ([@B13], [@B47], [@B48]). PS has long lasting consequences on α7nACh-ergic signaling in frontal cortex and hippocampus reducing the expression of α7nAChR protein expression in the brain of adult rats ([@B47]).

It is plausible to conclude that low grade neuroinflammation results in changes similar to those induced by PS with regard to reprogramming astrocytes to a higher glutamate uptake. As shown elsewhere ([@B49]), PS and exposure to endotoxin may act synergistically to exacerbate the impairment of neuron-glial glutamatergic interaction. For endotoxin exposure, this process is not subject to cholinergic modulation. Whether or not PS effects alone on astrocytes glutamate uptake can be ameliorated or reversed by α7nAChR agonism remains to be investigated.

The phylogenetically conserved interaction between neuroinflammation and chronic stress has been the subject of multiple studies ([@B24]), yet we are only beginning to unravel the complex web of interactions, across developmental stages, organs, cell types and species-specific differences, which connect these two phenomena. While the role of microglia in this context has been appreciated, the response of astrocytes we report here and their behavior on protein level under second hit scenario are novel observations warranting further studies in different species.

In summary, we show that genes involved in stress memory of the offspring are also impacted by LPS stress, this impact is further altered by a second hit (memory) and that such memory of LPS stress is amenable to cholinergic treatment via α7nAChR. It remains to be validated in future studies whether, when and which stimulation of the α7nAChR is favorable.
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